You are here:

daptomycin 500 mg powder for intravenous infusion (Cubicin)

Advice

Following an abbreviated submission

daptomycin 500 mg powder for intravenous infusion (Cubicin®) is accepted for restricted use within NHS Scotland for the treatment of complicated skin and soft-tissue infections in adults.

Daptomycin should be restricted to use in patients with known or suspected methicillin-resistant Staphylococcus aureus (MRSA) infection and on the advice of local microbiologists or specialists in infectious disease.

The new strength allows patients weighing over 87.5 kg to be treated with a single 500mg vial at a reduced cost compared to two vials of the 350 mg strength.

Daptomycin has a higher acquisition cost than some alternative treatments; it does not, however, require therapeutic drug monitoring.

Drug Details

Drug Name: daptomycin 500 mg powder for intravenous infusion (Cubicin)
SMC Drug ID: 338/06
Manufacturer: Novartis Pharmaceuticals UK Ltd
Indication: Complicated skin and soft-tissue infections in adults
BNF Category:
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 15 January 2007

Back